MOTS-c vs SS-31

The Dose Guy’s verdict

Oct 27, 2026
8 sources

Both are mitochondrial peptides, and they answer different questions. If you want energy and endurance that hold up in training, especially in a deficit, MOTS-c is the one I’d run, on a short course and logged. SS-31 is the one with human trials, built to repair mitochondria that are already failing; if you are older and the goal is the engine rather than the gym, it is the one to try, but expect little, because its best anti-aging result faded within a week. Run one at a time, and never start both at once.

Which would I take?MOTS-c for training, short and logged.

How they differ

The biggest difference is what each one does to the cell. MOTS-c is a signal: your mitochondria release it when energy runs short, and it tells the cell to adapt through AMPK, the same energy sensor that exercise and fasting switch on. That is why people pin it around fasted cardio and run it through a cut. SS-31, elamipretide in its trials, is a repair part. It parks on the inner mitochondrial membrane, on a lipid called cardiolipin, and holds the energy-making machinery together so it leaks less. One tells the cell to train like it is short on fuel; the other patches the engine.

That decides who each one is for. A healthy lifter’s mitochondria are not broken, so SS-31 has little to patch, and its trials keep missing their main targets even in people whose mitochondria are genuinely damaged. MOTS-c has the opposite problem: a good mouse story on performance and metabolic aging, and that is where its evidence stops. Neither is a recovery peptide in the gym sense. For a tendon or a pulled muscle, that is BPC-157.

The weekly rhythm differs too. MOTS-c is a few pins a week, timed to training. SS-31 is a daily pin with a big trial dose behind it, so the commitment and the injection-site welts pile up faster.

What the research shows

Nobody has run these two against each other, and they sit on different floors: SS-31 has human trials that mostly missed, MOTS-c has mice and a dish.

No head-to-head trial of MOTS-c against SS-31 exists, and no controlled human trial of injected MOTS-c exists at all.as of Aug 2026

MOTS-c enhanced physical performance in young, middle-aged, and old mice, and treatment begun at 23.5 months increased physical capacity and healthspan.Nat Commun 2021 · mouse aging

In adipose-derived stromal cells from six donors with obesity, exogenous MOTS-c reduced proliferation and increased p16, p21, and TNF-alpha expression. A dish, not a person, and still the only safety signal MOTS-c has.Inflamm Regen 2026 · in vitro

In 39 older adults with poorly functioning mitochondria, a single elamipretide infusion raised muscle mitochondrial ATPmax versus placebo immediately, p=0.045, but not at day 7, and hand-muscle fatigue resistance did not change.2021 · RCT · n=39

MMPOWER-3, in primary mitochondrial myopathy: the week-24 placebo-adjusted 6-minute walk difference on 40 mg daily was -3.2 m, 95% CI -18.7 to 12.3, p=0.69.NMD 2023 · phase 3 · n=218

SS-31 is the better-measured pin and MOTS-c the more interesting one for training. Neither has shown a healthy person anything that lasts.

How people run them

MOTS-c, the way the community runs it: 5 to 10 mg sub-q, two to four times a week, pinned around fasted training or through a cut. That is forum consensus, not a study dose. Keep the course short and judge it in the first few weeks; if the energy shift has not shown by then, it is not coming at that dose.

SS-31 is a daily pin. Most people start around 5 to 10 mg a day and assess over weeks before going anywhere near the 40 mg trial dose, and run it as a defined block of 8 to 12 weeks.

Switching is simple: stop one, start the other at its own starting dose the next day, no overlap. Stacking them is a forum staple, usually with NAD+ on top, and I would not start them together. Nobody knows how they interact, and if you feel something you will not know which one did it. Run one, learn your baseline, and only then add the second.

MOTS-c5–10 mg, 2–4x/wkForum consensus, not a study dose. Time it around fasted training.

SS-315–10 mg/day startWhere most people begin; 40 mg/day is the trial dose, not the target.

Course8–12 weeksThe usual SS-31 block. MOTS-c runs shorter and gets judged early.

Switchingnext day, no overlapStart the new one at its own starting dose.

Stackingone at a timeAdd the second only after the first has shown you something.